Amoxicillin Trihydrate

Omega-3 and low-dose aspirin matched the effectiveness of antibiotics in a year-long study of patients with severe gum disease, with both approaches helping about 58% reach the treatment goal. The unexpected result could point to a new way to treat some patients while reducing reliance on antibiotics and the growing problem of antibiotic resistance.A combination of omega-3 and low-dose acetylsalicylic acid (ASA) performed about as well as antibiotics in a yearlong study of people with severe periodontitis, raising the possibility of an alternative treatment for some patients. The research was conducted by scientists affiliated with Albert Einstein Israelite Hospital, Guarulhos University (UNG), the University of Taubaté (UNITAU), and the Ribeirão Preto School of Dentistry at USP (FORP-USP) in Brazil, along with Harvard University in the United States. The findings were published in the Journal of Periodontology. Researchers say the results could eventually help reduce antibiotic use in selected patients, an important consideration as bacterial resistance becomes an increasingly serious global health problem. Severe Periodontitis Can Damage Bone and Teeth Supported by FAPESP (projects 20/05874-2 and 20/05875-9), the clinical study included 109 people with advanced periodontitis who were followed for one year. Periodontitis is a chronic inflammatory disease that develops when bacteria accumulate below the gumline and damage the tissues that hold teeth in place. In advanced cases, the disease can destroy supporting bone, loosen teeth, and eventually cause tooth loss. "Patients with severe disease have very deep pockets, which act as reservoirs for bacteria associated with the disease. It's a very challenging condition to treat," says dental surgeon Nídia Cristina Castro dos Santos, the first author of the study and a professor and researcher at Einstein. Researchers Compared Four Treatment Strategies The participants were randomly divided into four groups. Everyone received subgingival instrumentation, popularly known as scaling, which is a standard treatment for periodontitis. The procedure removes bacterial deposits and other material from below the gums. What differed among the groups was the additional treatment they received. Participants in the control group were given placebo versions of the antibiotics, omega-3, and ASA, packaged in capsules that looked like the active treatments. A second group received the antibiotics metronidazole and amoxicillin. This combination has some of the strongest scientific evidence supporting its use in severe periodontitis. Patients took the antibiotics three times per day for 14 days. A third group received three grams of omega-3 each day along with a daily dose of aspirin for six months. The fourth group received both approaches, taking antibiotics for two weeks while also following the omega-3 and ASA regimen for six months. Researchers assessed the participants again after three, six, and twelve months. Omega-3 and Aspirin Nearly Matched Antibiotics After one year, about 58% of patients treated with antibiotics had reached the clinical target established by the researchers. That goal was defined as having no more than four remaining deep periodontal pockets. The omega-3 and ASA group achieved a nearly identical result, with 57.7% of participants reaching the same target. The difference compared with standard treatment alone was substantial. Among patients who received scaling plus placebo, only 23.1% met the clinical goal. Surprisingly, using antibiotics together with omega-3 and ASA did not produce any additional benefit over either strategy alone. "The use of antibiotics isn't considered the gold standard of treatment. Although metronidazole and amoxicillin yield good results in the most severe cases, their use should be evaluated on a case-by-case basis due to risks related to bacterial resistance and possible adverse effects," says Castro dos Santos. Earlier Research Pointed to Omega-3's Potential The findings build on previous work examining omega-3 and inflammation in periodontal disease. In an earlier FAPESP-supported study published in Scientific Reports, researchers found that omega-3 supplementation reduced inflammation and bone loss associated with periodontal disease in rats. The effect was particularly noticeable when supplementation was combined with physical exercise. Because that research used an animal model, it could not establish whether the same effects would occur in people. However, it provided evidence that omega-3 might influence inflammatory processes involved in oral disease. Helping the Body Resolve Inflammation According to Castro, omega-3 works differently from conventional anti-inflammatory medications. Rather than simply blocking particular inflammatory pathways, omega-3 can contribute to the production of molecules that help the body naturally bring inflammation to an end and promote tissue repair. Low-dose ASA was included because it can enhance the production of these inflammation-resolving molecules. Researchers therefore suspected that combining omega-3 with ASA might help the body gain better control over the persistent inflammation associated with periodontitis. "We imagined that the combination of antibiotics and omega-3 would be most effective in controlling periodontitis in these patients. We also believed that the results for the group that used omega-3 with ASA would be slightly lower than those for the antibiotic group. The result was surprising because the two therapies performed very similarly, paving the way for it to become a treatment option for these patients," says Castro. Benefits Continued After Treatment Ended The researchers were also struck by how long the apparent benefits lasted. Participants who had taken omega-3 and ASA continued to show results similar to those seen at the end of treatment even six months after supplementation had stopped. According to Castro, the persistence of the effect raises the possibility that changing the way the body responds to inflammation could produce longer-lasting benefits. Researchers are still investigating exactly how this might happen. For dental surgeon Magda Feres, the lead author of the study and a full professor at the Harvard School of Dental Medicine and the Graduate Program in Dentistry at UNG, the results suggest that targeting the inflammatory response could provide another option for certain patients. "The combination of omega-3 and low-dose aspirin achieved clinical benefits comparable to those of the metronidazole and amoxicillin protocol, opening up a real alternative for those who can't take antibiotics, especially patients with allergies or intolerance to these medications," she says. A Possible Way to Reduce Antibiotic Use The potential to treat some cases without antibiotics is particularly relevant because antibiotic resistance is considered one of the major threats to global public health. When bacteria are repeatedly exposed to antibiotics, strains that can survive the drugs may spread, making infections more difficult to treat. Reducing unnecessary antibiotic use is therefore an important public health goal. "Demonstrating that it's possible to treat severe periodontitis by modulating the body's own response is new and relevant information that helps preserve antibiotics for when they are truly indispensable," says Feres. More Evidence Is Needed Despite the promising results, the researchers stress that omega-3 and aspirin should not yet be viewed as a routine replacement for antibiotics in severe periodontitis. The clinical trial included patients who did not have significant systemic or oral diseases. Additional studies will be needed to determine whether the findings hold true in broader and more diverse populations, and to establish which patients are most likely to benefit from each treatment strategy. Researchers are also conducting microbiological analyses to understand what happens to bacteria inside periodontal pockets during treatment. Preliminary findings suggest that the therapies may reduce bacterial species associated with periodontal disease while increasing microorganisms linked to healthier gums. "It's an important step forward, but not the end of the story. Therefore, the message is one of cautious optimism: we have a promising, scientifically plausible alternative to antibiotics in select cases. Routine replacement will require more evidence," she concludes.

Antibiotic adjuvants blocking host-cell invasion pathways represents a promising new direction in periodontitis management CHINA, July 27, 2026 / EINPresswire.com / -- Porphyromonas gingivalis can evade antibiotics by invading host cells, contributing to recurrent periodontitis and persistent tissue damage. A new study reveals that blocking host-cell invasion pathways significantly reduced infection. Simvastatin, a widely used cholesterol-lowering drug, emerged as an effective antibiotic adjuvant, enhancing bacterial clearance, promoting bone-forming activity, and improving treatment outcomes in a rat model of periodontitis. The findings highlight the importance of antibiotic adjuvants in periodontitis treatment. Periodontitis is a chronic inflammatory disease caused by bacterial infection and an imbalance in the community of microorganisms beneath the gums. Although conventional treatments target dental plaque bacteria, they often fail to completely eliminate the infection. One reason is that Porphyromonas gingivalis (P. gingivalis), a major periodontal pathogen, can invade and hide inside host cells, allowing it to evade antibiotics and later re-emerge to cause recurrent disease. To address this challenge, a research team led by Professor Cun-yu Wang from the Institute of Advanced Clinical Medicine, Peking University, investigated a host-directed therapeutic strategy that prevents P. gingivalis from invading host cells rather than directly targeting the bacteria. The researchers also evaluated the potential of combining simvastatin or YH-306 with metronidazole, a commonly prescribed antibiotic for periodontitis. Their findings were published in Volume 18 of the International Journal of Oral Science on July 9, 2026. “The core of this strategy lies in applying host-directed adjuvant therapy to interfere with the pathogenic process. Using adjuvants to block bacterial adhesion and invasion is often considered as a promising, host-directed therapeutic strategy,” says Prof. Wang. “For our study, we evaluated the efficacy of several invasion inhibitors as antibiotic adjuvants in periodontal host cells.” The study examined four compounds with distinct mechanisms of action, each for a specific host target that P. gingivalis uses during infection. FT011 was used to target type I collagen, ATN-161 to inhibit integrin β1, YH-306 to suppress focal adhesion kinase signaling, and simvastatin, a widely prescribed cholesterol-lowering drug, to reduce lipid raft formation on host cell membranes. Using human oral keratinocytes and periodontal ligament stem cells (PDLSCs), the researchers established laboratory models of P. gingivalis infection and evaluated how effectively these compounds could interfere with bacterial invasion. Among the tested agents, simvastatin and YH-306 emerged as particularly promising candidates. Both significantly reduced bacterial adhesion and invasion while maintaining favorable safety profiles in host cells. Simvastatin showed an additional advantage, as it enhanced the ability of host cells to clear bacteria that had already entered cells. The treatment also restored the osteogenic potential of infected PDLSCs, helping reverse the negative effects of infection on bone-forming activity. Since destruction of the supporting bone around teeth is a hallmark of periodontitis, this finding could have important therapeutic implications. To explore the potential of these host-directed agents as antibiotic adjuvants, the team combined the host-targeting compounds with commonly used periodontal antibiotics, including metronidazole, tetracycline, and amoxicillin. The results revealed notable synergistic effects. Simvastatin reduced the amount of metronidazole needed to suppress intracellular bacteria by more than 40% and nearly halved the required tetracycline dose. FT011 showed the strongest synergy with amoxicillin, reducing the required antibiotic dose by more than 50%. The host-directed compounds also reduced invasion by other clinically relevant periodontal pathogens, including Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans. This suggests that targeting host invasion pathways may represent a broader strategy for combating polymicrobial periodontal infections rather than focusing on a single bacterial species. To determine whether these laboratory findings translated into real-world therapeutic benefits, the researchers tested the approach in a rat model of periodontitis. Animals receiving combined treatment with metronidazole and either simvastatin or YH-306 showed substantially improved outcomes compared with antibiotic treatment alone. The combination therapies reduced bacterial burden, limited inflammatory responses, preserved alveolar bone structure, and decreased bone resorption. Among the tested regimens, the simvastatin–metronidazole combination produced the most pronounced benefits, significantly improving bone volume and reducing intracellular bacterial reservoirs. “Our study highlights an emerging concept in infectious disease treatment, as the approach can reduce antibiotic requirements, limit the development of antimicrobial resistance, and preserve beneficial microbial communities,” explains Prof. Wang. Although additional research is needed to optimize drug delivery and confirm long-term safety and efficacy in humans, the findings suggest that host-directed antibiotic adjuvants could represent a new frontier in periodontal therapy. By preventing bacteria from invading host cells while simultaneously enhancing tissue regeneration, this strategy may offer a more effective way to break the cycle of recurrent infection and progressive periodontal destruction. Reference Title of original paper: P. gingivalis-host interactions direct antibiotic adjuvants for periodontitis antimicrobial therapy Journal: International Journal of Oral Science DOI: https://doi-org.libproxy1.nus.edu.sg/10.1038/s41368-026-00448-1 About Peking University Founded in 1898 as the Imperial University of Peking, Peking University (PKU) is China’s first national comprehensive university. Located in Beijing, it is a global academic powerhouse consistently ranked among the top universities in Asia and the world It has six faculties, namely Humanities, Social Sciences, Economics and Management, Science, Information Technology and Engineering, as well as Health Science. It consists of 55 schools and departments, 60 research entities, and ten affiliated hospitals. By optimizing disciplines and specialties, it remains a premier institution for research and international exchange in the current times. Website: https://english.pku.edu.cn/ About Professor Cun-yu Wang from Peking University, China Dr. Cun-yu Wang serves as an Adjunct Professor at the Institute of Advanced Clinical Medicine, Peking University. He studied at Nanjing Medical University and Peking University’s School of Dentistry, where he obtained his undergraduate and doctoral degrees in 1985 and 1989, respectively. He primarily engages in cutting-edge research on the molecular pathogenesis of oral diseases and was the first to discover TNF-activated nuclear factor kappa B. He has published more than 200 peer-reviewed papers in prestigious journals, including Science, Cell, Nature Biotechnology, and Nature Medicine. Funding information This study was supported by the Beijing Natural Science Foundation (Grant Nos. L222144, L242158, and L246035) and Peking University Third Hospital Fund for Interdisciplinary Research (BYSYJC2025057). Yini Bao International Journal of Oral Science +862885546461 ext. email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.